CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Scientific Officer sold 6,797 shares at $15.15 ($103,003)
- 4 Grant or award Chief Scientific Officer acquired 7,200 shares (grant or award)
- 4 Grant or award President and CFO acquired 20,300 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 8,400 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 23,900 shares (grant or award)
- 4 Planned sale President and CFO sold 4,501 shares at $16.94 ($76,247)
- 4 Open-market buy 10% owner bought 48,770 shares at an average $25.83 ($1,259,623)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy President and CFO bought 24,000 shares at $20.48 ($491,400)
- 4 Open-market buy Chief Executive Officer bought 47,500 shares at $20.40 ($969,000)
Page 2 of 15 · 287 filings